Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
19:59:50 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



News for U:GERN from 2023-05-18 to 2024-05-17 - 43 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-16 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-02 07:00U:GERNNews ReleaseGeron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
2024-04-25 16:30U:GERNNews ReleaseGeron to Announce First Quarter 2024 Financial Results on May 2, 2024
2024-04-18 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-03 16:30U:GERNNews ReleaseGeron to Participate at Upcoming Investor Conferences in April
2024-03-19 09:07U:GERNNews ReleaseGeron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2024-03-14 15:54U:GERNNews ReleaseGeron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk MDS
2024-02-28 07:05U:GERNNews ReleaseGeron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
2024-02-22 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-14 16:30U:GERNNews ReleaseGeron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
2024-01-18 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-12 08:30U:GERNNews ReleaseGeron to Participate in the B. Riley Securities Virtual Oncology Conference
2023-12-21 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-12-11 16:15U:GERNNews ReleaseGeron Announces IMerge Phase 3 Presentations at ASH Highlighting Significant Durability of Transfusion Independence and Breadth of Effect Across MDS Subgroups with Imetelstat in Lower Risk MDS
2023-12-06 08:00U:GERNNews ReleaseGeron Announces Fifty Percent Enrollment in the Phase 3 IMpactMF Clinical Trial Evaluating Imetelstat in Patients with Relapsed/Refractory Myelofibrosis
2023-12-04 05:00U:GERNNews ReleaseGeron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS
2023-11-28 08:00U:GERNNews ReleaseGeron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors
2023-11-16 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 16:30U:GERNNews ReleaseGeron to Participate at Upcoming Investor Conferences in November
2023-11-02 09:00U:GERNNews ReleaseGeron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS
2023-11-02 08:00U:GERNNews ReleaseGeron Corporation Reports Business Highlights and Third Quarter 2023 Financial Results
2023-10-26 16:30U:GERNNews ReleaseGeron to Announce Third Quarter 2023 Financial Results on November 2, 2023
2023-10-19 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-29 08:00U:GERNNews ReleaseGeron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS
2023-09-11 16:30U:GERNNews ReleaseGeron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer
2023-09-07 08:00U:GERNNews ReleaseGeron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting
2023-09-05 16:30U:GERNNews ReleaseGeron to Participate in the Baird 2023 Global Healthcare Conference
2023-08-22 08:00U:GERNNews ReleaseGeron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
2023-08-21 08:00U:GERNNews ReleaseGeron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS
2023-08-17 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 16:05U:GERNNews ReleaseGeron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results
2023-07-27 16:30U:GERNNews ReleaseGeron to Announce Second Quarter 2023 Financial Results on August 3, 2023
2023-07-20 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-29 08:30U:GERNNews ReleaseGeron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS
2023-06-22 16:30U:GERNNews ReleaseGeron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 09:00U:GERNNews ReleaseGeron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat
2023-06-13 09:00U:GERNNews ReleaseGeron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS
2023-06-12 08:00U:GERNNews ReleaseGeron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients
2023-06-07 16:30U:GERNNews ReleaseGeron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
2023-06-06 16:30U:GERNNews ReleaseGeron to Host Virtual Investor Event on June 14, 2023
2023-06-02 15:30U:GERNNews ReleaseGeron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients
2023-05-25 17:02U:GERNNews ReleaseGeron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3
2023-05-18 16:30U:GERNNews ReleaseGeron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)